Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2017

View Archived Issues

Galapagos initiates phase I trial of cystic fibrosis C2 corrector GLPG-3221

First subject dosed in phase III study of Nevakar's ophthalmic solution for myopia in children

Novel COMT inhibitors as candidates for dopaminergic-related cognitive and motor deficits

BTRX-335140, a potent and reversible KOR antagonist with promising in vivo activity

LDN/OSU-215111 shows promise in preclinical models of Alzheimer's disease and Gulf War illness

Beactica receives funding to develop novel and potent allosteric LSD1 modulators

Supplemental NDA seeks to expand Trelegy Ellipta label in U.S.

Prometic Life Sciences reports interim data from IVIG phase III trial

Teijin's TEI-A reduces uric acid levels in preclinical tests

Rupafin set for Japanese launch

Shionogi & Co. patents new AMPK activators for diabetes

Phase II trials of milciclib in thymic carcinoma and thymoma meet primary endpoints

Bavencio launched in Japan

Perrigo completes divestiture of API business

Innate Pharma offers update on lirilumab program

Sage Therapeutics discloses novel NMDA receptor modulators

Shenogen Pharma and Lee's Pharm collaborate to develop combination product for late-stage cancer

Fochon Pharma presents novel CDK4/6 inhibitors

DSMB recommends continuation of RESOLVE-IT study of elafibranor in NASH

Immunovaccine discloses vaccine compositions for cancer

European Commission approves Tremfya

New vasopressin receptor antagonists presented by Bayer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...